Silibinin attenuates high-fat diet-induced renal fibrosis of diabetic nephropathy

References

• Tripathi BK, Srivastava AK. Diabetes mellitus: complications and therapeutics. Med Sci Monit. 2006;12:RA130–RA147.16810145
   PubMed Web of Science ®Google Scholar
• NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513–1530. doi:10.1016/S0140-6736(16)00618-827061677
   PubMed Web of Science ®Google Scholar
• Mokashi P, Bhatt LK, Khanna A, Pandita N. Swertisin rich fraction from Enicostema littorale ameliorates hyperglycemia and hyperlipidemia inhigh-fat fed diet and low dose streptozotacin induced type 2 diabetes mellitus in rats. Biomed Pharmacother. 2017;96:1427–1437. doi:10.1016/j.biopha.2017.09.15329031588
   PubMed Web of Science ®Google Scholar
• Matheus VA, Monteiro L, Oliveira RB, Maschio DA, Collares-Buzato CB. Butyrate reduces high-fat diet-induced metabolic alterations, hepatic steatosis and pancreatic beta cell and intestinal barrier dysfunctions in prediabetic mice. Exp Biol Med (Maywood). 2017;242:1214–1226. doi:10.1177/153537021770818828504618
   PubMed Web of Science ®Google Scholar
• Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014;11:1185–1200. doi:10.7150/ijms.1000125249787
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG. Diabetic nephropathy: new risk factors and improvements in diagnosis. Rev Diabet Stud. 2015;12:110–118. doi:10.1900/RDS.2015.12.11026676664
   PubMedGoogle Scholar
• Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014;124:2333–2340. doi:10.1172/JCI7227124892707
   PubMed Web of Science ®Google Scholar
• Furuichi K, Shimizu M, Okada H, Narita I, Wada T. Clinico-pathological features of kidney disease in diabetic cases. Clin Exp Nephrol. 2018;22:1046–1051. doi:10.1007/s10157-018-1556-429564666
   PubMed Web of Science ®Google Scholar
• Tang F, Hao Y, Zhang X, Qin J. Effect of echinacoside on kidney fibrosis by inhibition of TGF-β1/Smads signaling pathway in the db/db mice model of diabetic nephropathy. Drug Des Devel Ther. 2017;11:2813–2826. doi:10.2147/DDDT.S143805
   PubMed Web of Science ®Google Scholar
• Zanchi C, Macconi D, Trionfini P, et al. MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. Diabetologia. 2017;60:1114–1125. doi:10.1007/s00125-017-4248-928364255
   PubMed Web of Science ®Google Scholar
• Lopez-Hernandez FJ, Lopez-Novoa JM. Role of TGF-beta in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res. 2012;347:141–154. doi:10.1007/s00441-011-1275-622105921
   PubMed Web of Science ®Google Scholar
• Klemis V, Ghura H, Federico G, et al. Circulating fibronectin contributes to mesangial expansion in a murine model of type 1 diabetes. Kidney Int. 2017;91:1374–1385. doi:10.1016/j.kint.2016.12.00628159318
   PubMed Web of Science ®Google Scholar
• Wang D, Lin N, Tang Y, Lu H. Inhibition of P2Y11R ameliorated TNF-alpha-induced degradation of extracellular matrix in human chondrocytic SW1353 cells. Am J Transl Res. 2019;11:2108–2116.31105822
   PubMed Web of Science ®Google Scholar
• Zent R, Yan X, Su Y, et al. Glomerular injury is exacerbated in diabetic integrin alpha1-null mice. Kidney Int. 2006;70:460–470. doi:10.1038/sj.ki.500035916775606
   PubMed Web of Science ®Google Scholar
• Toth-Manikowski S, Atta MG. Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res. 2015;2015:697010. doi:10.1155/2015/81583926064987
   PubMed Web of Science ®Google Scholar
• Kim Y, Park CW. New therapeutic agents in diabetic nephropathy. Korean J Intern Med. 2017;32:11–25. doi:10.3904/kjim.2016.17428049280
   PubMed Web of Science ®Google Scholar
• Bahmani M, Shirzad H, Rafieian S, Rafieian-Kopaei M. Silybum marianum: beyond hepatoprotection. J Evid Based Complementary Altern Med. 2015;20:292–301. doi:10.1177/215658721557111625686616
   PubMedGoogle Scholar
• Zou H, Zhu XX, Zhang GB, et al. Silibinin: an old drug for hematological disorders. Oncotarget. 2017;8:89307–89314. doi:10.18632/oncotarget.1915329179521
   PubMedGoogle Scholar
• Zheng W, Feng Z, Lou Y, et al. Silibinin protects against osteoarthritis through inhibiting the inflammatory response and cartilage matrix degradation in vitro and in vivo. Oncotarget. 2017;8:99649–99665. doi:10.18632/oncotarget.2058729245931
   PubMedGoogle Scholar
• Yun DG, Lee DG. Assessment of silibinin as a potential antifungal agent and investigation of its mechanism of action. IUBMB Life. 2017;69:631–637. doi:10.1002/iub.164728636236
   PubMed Web of Science ®Google Scholar
• Haddad Y, Vallerand D, Brault A, et al. Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid Based Complement Alternat Med. 2011;2011:nep164. doi:10.1155/2011/19619019884114
   PubMed Web of Science ®Google Scholar
• Davatgaran-Taghipour Y, Masoomzadeh S, Farzaei MH, et al. Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective. Int J Nanomedicine. 2017;12:2689–2702. doi:10.2147/IJN.S13197328435252
   PubMed Web of Science ®Google Scholar
• Guigas B, Naboulsi R, Villanueva GR, et al. The flavonoid silibinin decreases glucose-6-phosphate hydrolysis in perfused rat hepatocytes by an inhibitory effect on glucose-6-phosphatase. Cell Physiol Biochem. 2007;20:925–934. doi:10.1159/00011045317982275
   PubMed Web of Science ®Google Scholar
• Liu Y, Ye J, Cao Y, et al. Silibinin ameliorates diabetic nephropathy via improving diabetic condition in the mice. Eur J Pharmacol. 2019;845:24–31. doi:10.1016/j.ejphar.2018.12.03130597130
   PubMed Web of Science ®Google Scholar
• Lu Q, Ma Z, Ding Y, et al. Circulating miR-103a-3p contributes to angiotensin II-induced renal inflammation and fibrosis via a SNRK/NF-kappaB/p65 regulatory axis. Nat Commun. 2019;10:2145. doi:10.1038/s41467-019-10116-031086184
   PubMed Web of Science ®Google Scholar
• Zhang M, Yang XJ. Effects of a high fat diet on intestinal microbiota and gastrointestinal diseases. World J Gastroenterol. 2016;22:8905–8909. doi:10.3748/wjg.v22.i40.890527833381
   PubMed Web of Science ®Google Scholar
• Hariri N, Thibault L. High-fat diet-induced obesity in animal models. Nutr Res Rev. 2010;23:270–299. doi:10.1017/S095442241000016820977819
   PubMed Web of Science ®Google Scholar
• Kanno A, Asahara SI, Masuda K, et al. Compensatory hyperinsulinemia in high-fat diet-induced obese mice is associated with enhanced insulin translation in islets. Biochem Biophys Res Commun. 2015;458:681–686. doi:10.1016/j.bbrc.2015.02.02425686499
   PubMed Web of Science ®Google Scholar
• Saravanan S, Pari L. Protective effect of thymol on high fat diet induced diabetic nephropathy in C57BL/6J mice. Chem Biol Interact. 2016;245:1–11. doi:10.1016/j.cbi.2015.11.03326680107
   PubMed Web of Science ®Google Scholar
• Wu CC, Hung CN, Shin YC, Wang C-J, Huang H-P. Myrciaria cauliflora extracts attenuate diabetic nephropathy involving the Ras signaling pathway in streptozotocin/nicotinamide mice on a high fat diet. J Food Drug Anal. 2016;24:136–146. doi:10.1016/j.jfda.2015.10.00128911396
   PubMed Web of Science ®Google Scholar
• Li X, Wang L, Gao X, et al. Mechanisms of protective effect of Ramulus Mori polysaccharides on renal injury in high-fatdiet/streptozotocin-induced diabetic rats. Cell Physiol Biochem. 2015;37:2125–2134. doi:10.1159/00043857026599870
   PubMedGoogle Scholar
• Chu C, Li D, Zhang S, et al. Role of silibinin in the management of diabetes mellitus and its complications. Arch Pharm Res. 2018;41:785–796. doi:10.1007/s12272-018-1047-x29978427
   PubMed Web of Science ®Google Scholar
• Khazim K, Gorin Y, Cavaglieri RC, Abboud HE, Fanti P. The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo. Am J Physiol Renal Physiol. 2013;305:F691–F700. doi:10.1152/ajprenal.00028.201323804455
   PubMed Web of Science ®Google Scholar
• Kim JS, Han NK, Kim SH, Lee H-J. Silibinin attenuates radiation-induced intestinal fibrosis and reverses epithelial-to-mesenchymal transition. Oncotarget. 2017;8:69386–69397. doi:10.18632/oncotarget.2062429050211
   PubMedGoogle Scholar
• Son Y, Lee HJ, Rho JK, et al. The ameliorative effect of silibinin against radiation-induced lung injury: protection of normal tissue without decreasing therapeutic efficacy in lung cancer. BMC Pulm Med. 2015;15:68. doi:10.1186/s12890-015-0055-626143275
   PubMed Web of Science ®Google Scholar
• Ezhilarasan D, Karthikeyan S, Vivekanandan P. Ameliorative effect of silibinin against N-nitrosodimethylamine-induced hepatic fibrosis in rats. Environ Toxicol Pharmacol. 2012;34:1004–1013. doi:10.1016/j.etap.2012.07.00422986105
   PubMed Web of Science ®Google Scholar
• Moynagh PN. The NF-κB pathway. J Cell Sci. 2005;118:4589–4592. doi:10.1242/jcs.0257916219681
   PubMedGoogle Scholar
• Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107:135–142. doi:10.1172/JCI1191411160126
   PubMed Web of Science ®Google Scholar
• Tian L, Li W, Wang T. Therapeutic effects of silibinin on LPS-induced acute lung injury by inhibiting NLRP3 and NF-κB signaling pathways. Microb Pathog. 2017;108:104–108. doi:10.1016/j.micpath.2017.05.01128483599
   PubMed Web of Science ®Google Scholar
• Raina K, Agarwal C, Agarwal R. Effect of silibinin in human colorectal cancer cells: targeting the activation of NF-κB signaling. Mol Carcinog. 2013;52:195–206. doi:10.1002/mc.2184322086675
   PubMed Web of Science ®Google Scholar
• Lv W, Booz GW, Wang Y, Fan F, Roman RJ. Inflammation and renal fibrosis: recent developments on key signaling molecules as potential therapeutic targets. Eur J Pharmacol. 2018;820:65–76. doi:10.1016/j.ejphar.2017.12.01629229532
   PubMed Web of Science ®Google Scholar
• Huang J, Chen Z, Li J, et al. Protein kinase CK2α catalytic subunit ameliorates diabetic renal inflammatory fibrosis via NF-κB signaling pathway. Biochem Pharmacol. 2017;132:102–117. doi:10.1016/j.bcp.2017.02.01628237649
   PubMed Web of Science ®Google Scholar
• Huang J, Li J, Chen Z, et al. Sphingosine kinase 1 mediates diabetic renal fibrosis via NF-κB signaling pathway: involvement of CK2α. Oncotarget. 2017;8:88988–89004. doi:10.18632/oncotarget.2164029179493
   PubMedGoogle Scholar